COVID-19抗原、抗體、中和抗體檢驗於國內外之應用經驗

何美鄉

2021.9.24

FOR 新冠肺炎快篩檢驗及應用研討會


COVID–19 Diagnostic tests

>In the lab test

or


> at the point of care /service

> Consider that the Pathogen is evolving




Source: Augustine J. Clin. Med. 2020, 9, 3372; doi:10.3390/jcm9103372

COVID—19 病人 檢驗試劑的標的 病毒核酸與保護性抗體




此示意圖,不適用於無症狀感染者;僅適用於有症狀的病人。 This figure is not applicable for asymptomatic COVID-19 infection

COVID-19 在病人鼻咽拭子與痰中 Q-PCR CT 值與病毒陽性率的相關性








糞便核酸數量:中位數 12,882 copies/g (0~600,000 to 30,000,000)

糞便中培養不出病毒


病毒培養:咽喉核酸數量>106才有陽 性病毒培養

Source: Wolfel et al., Nature | Vol 581 | 28 May 2020 | 465







Arons et al, n engl j med 382;22 nejm.org May 28, 2020




• 感染10天後,不具感染性



發病日的病毒量在鼻胭喉的表皮細胞已達最高 發病日的病毒量在鼻胭喉的表皮細胞已達最高



疫情的擴散與演進



受疫情影響的各國,都以相當極端的手段,停工、停課、禁航等,來防 疫,因為病人癱瘓醫療體系。達到群族免疫之前疫情會持續蔓延

Is there a long-term niche for Ag tests?

案例 EU Digital COVID Certificate

Is a digital proof that a person has either

- been vaccinated against COVID-19 or
- received a negative test result or
- recovered from COVID-19

COVID -19 Diagnostic tests

WHO sensitivity >80% specificity >97%

EU sensitivity >90% specificity >97%



Vaccination one dose 81%, two doses 79%

> Despite rising confirmed cases, the severe case number remains low

Singapore reported daily 1,178 new cases of Covid-19 this week

>Of the more than 13,000 people infected over the last four weeks the health ministry said, 98 per cent had no or mild symptoms.

Facing uncertainty

> Beginning 9/18 ART (Antigen Rapid Test) sold in vending machine



Before Nov 2021


>a negative COVID-19 test, taken within three (3) calendar days of departure, or

 \succ proof of recovery from the virus within the last 90 days.

November and onwards

Fully vaccinated

> a negative COVID-19 test, taken within three (3) calendar days of departure



If the United States were an international destination, more than 80% of states would <u>qualify for a Level 4 "Do Not Travel" designation</u> by the Centers for Disease Control and Protection (CDC).

For travel within the U.S., CDC guidance depends on an individual's vaccination status. The <u>agency recommends</u> that Americans <u>delay all travel</u> until they are fully vaccinated. If that is not possible, the CDC asks that unvaccinated travelers take a Covid-19 viral test one to three days before departure. Then, during the trip, travelers should practice social distancing and wear a face mask while indoors in public settings and in crowded venues. Lastly, the CDC recommends that unvaccinated travelers get a viral test three to five days after returning home and self-quarantine for one week.




Fully Vaccinated are exempt from quarantine

Tests for all entrys; Tests accepted LAMP, NAAT, NEAR, PCR, SDA and TMA tests.

Vaccination status 70% 42%

Testing for neutralization antibody

- Laborious work
- > necessary for vaccine efficacy/effective evaluation
- > Replaced by surrogate antibody (IgG to S protein or to RBD)
- Need for P3 lab continue?



SARS-CoV-2

Antibody vaccine vs natural infection

 Antibody induced by gene-based or subunit protein-based vaccines

- Anti-S or anti-RBD
- Natural infection
 - Anti-N
 - N-terminus cross reactive with many coronavirus
 - C-terminus more specific for SARS-CoV-2

Diagnosis at Point of care/service (DIY)

Action taken after confirmed diagnosis

Immediate treatment

Effective drug available

Tracffic control

➢ Isolation

> Infection remains life threatening to substantial fraction of population

Diagnostic Test done the Lab

can be done in Large scale
more efficient / economical

In situations

Collective data needed

> Evaluation of vaccine, drug, and control strategy

Following the evolution of pathogen (molecular tests only)

General problem with DIY diagnostic test

> A number of COVID-19 tests available on the UK market failed to replicate their stated performance in technical and in use validation and real-world evidence collection.

Information about the true performance of COVID-19 test products is not easily accessible to consumers

> Consumers without access to information that would allow them to make informed choices about the tests they purchase.

Thank You!!